Number and Characteristics of Patients Receiving Opioid Treatment Programs (OTPs) in the US

"Facilities were asked how many clients in treatment on March 31, 2016, received medication-assisted opioid therapy drugs for detoxification or maintenance purposes. MAT includes the use of methadone and buprenorphine for the treatment of opioid addiction or dependence, and the use of extended-release injectable naltrexone (Vivitrol®) for relapse prevention in opioid addiction. Methadone is available only at OTP facilities that are certified by SAMHSA’s Center for Substance Abuse Treatment. Buprenorphine may be prescribed by physicians who have received DATA 2000 specific training and received a waiver to prescribe the medication for treatment of opioid addiction; some of these physicians are affiliated with facilities (either OTPs or other).22 All physicians or approved medical personnel can prescribe extended-release injectable naltrexone (Vivitrol®).
"• Of the total 1,150,423 clients in treatment, 365,064 (32 percent) received MAT in OTP facilities.
"• There were 345,443 clients receiving methadone in OTP facilities.
" • Of the clients receiving methadone, 215,576 clients (62 percent) were provided treatment at private for-profit OTPs and 109,504 clients (32 percent) were provided treatment at private non-profit OTPs.
"• There were 18,716 clients receiving buprenorphine in OTP facilities and 42,770 clients receiving buprenorphine in non-OTP facilities.
" • Of the clients receiving buprenorphine in OTPs, 12,495 clients (67 percent) were provided treatment at private for-profit OTPs and 4,675 clients (25 percent) were provided treatment at private non-profit OTPs.
" • Of the clients receiving buprenorphine in non-OTP facilities, 19,309 clients (45 percent) were provided treatment at private for-profit non-OTPs and 18,117 clients (42 percent) were provided treatment at private non-profit non-OTPs.
"• There were 905 clients receiving extended-release injectable naltrexone (Vivitrol®) in OTP facilities and 9,223 clients receiving extended-release injectable naltrexone (Vivitrol®) in non-OTP facilities.
" • Of the clients receiving extended-release injectable naltrexone (Vivitrol®) in OTPs, 500 clients (55 percent) were provided treatment at private non-profit OTPs and 251 clients (28 percent) were provided treatment at private for-profit OTPs.
" • Of the clients receiving extended-release injectable naltrexone (Vivitrol®) in non-OTP facilities, 4,464 clients (48 percent) were provided treatment at private non-profit non-OTPs and 3,085 clients (33 percent) were provided treatment at private for-profit non-OTPs."

Source: 

Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. Data on Substance Abuse Treatment Facilities. BHSIS Series S-93, HHS Publication No. (SMA) 17-5039. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017, pp. 30-31.
https://www.samhsa.gov/data/su...
https://www.samhsa.gov/data/si...

Region: 
Substance: